Everspin Technologies(US:MRAM)2024-05-02 20:01Revenue Performance - Total revenue decreased by $0.4 million, or 2.8%, from $14.8 million in Q1 2023 to $14.4 million in Q1 2024, primarily due to a $2.9 million decrease in product sales[73]. - Product sales accounted for $10.9 million, or 75% of total revenue in Q1 2024, down from $13.8 million, or 93% in Q1 2023[69]. - Licensing, royalty, patent, and other revenue increased by $2.5 million, or 234%, from $1.1 million in Q1 2023 to $3.6 million in Q1 2024, driven by RAD-Hard projects[74]. Expenses - Research and development expenses rose by $0.2 million, or 6.8%, from $3.2 million in Q1 2023 to $3.4 million in Q1 2024, primarily related to the new xSPI family of STT-MRAM products[79]. - General and administrative expenses increased by $0.8 million, or 25.3%, from $3.2 million in Q1 2023 to $4.0 million in Q1 2024, mainly due to stock-based compensation and professional services[81]. - Operating expenses increased to $8.76 million in Q1 2024, up from $7.73 million in Q1 2023, representing 61% of total revenue[69]. - Sales and marketing expenses remained consistent at $1.3 million for both Q1 2024 and Q1 2023, representing 9% of revenue[83]. Profitability - The net loss for Q1 2024 was $202,000 compared to a net income of $761,000 in Q1 2023[69]. - Gross margin slightly decreased from 56.8% in Q1 2023 to 56.5% in Q1 2024 due to reduced product sales and increased supplier pricing[77]. Cash Flow and Financial Position - As of March 31, 2024, cash and cash equivalents totaled $34.8 million, down from $36.9 million as of December 31, 2023, with no outstanding debt[86]. - Cash used in operating activities was $1.3 million in Q1 2024, compared to cash provided of $1.2 million in Q1 2023[89][90]. - Cash used in investing activities was $1.2 million in Q1 2024, reflecting purchases of manufacturing equipment, compared to $1.0 million in Q1 2023[91]. - Cash provided by financing activities was $0.4 million in Q1 2024, consisting of proceeds from the exercise of employee stock options, compared to cash used of $2.8 million in Q1 2023[92]. Other Financial Metrics - Total cost of sales decreased by $0.146 million, or 2.3%, from $6.416 million in Q1 2023 to $6.270 million in Q1 2024[75]. - Interest expense decreased by $0.1 million, or 100%, from $0.1 million in Q1 2023 to $0 in Q1 2024 due to the full repayment of the 2019 Credit Facility[84]. - Other income, net increased by $0.3 million, or 210.9%, from $0.4 million in Q1 2023 to $0.7 million in Q1 2024, primarily due to increased interest income[85]. Operational Challenges - The company continues to navigate the impacts of COVID-19, particularly in some Asian countries, while monitoring supply chain constraints[66].